| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2024 | $55.00 | Buy | Chardan Capital Markets |
| 7/26/2024 | $35.00 | Overweight | Morgan Stanley |
| 2/15/2024 | $50.00 | Buy | Canaccord Genuity |
4 - CervoMed Inc. (0001053691) (Issuer)
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp
SC 13G - CervoMed Inc. (0001053691) (Subject)
SC 13G - CervoMed Inc. (0001053691) (Subject)
SC 13G/A - CervoMed Inc. (0001053691) (Subject)
SC 13D/A - CervoMed Inc. (0001053691) (Subject)
Chardan Capital Markets initiated coverage of CervoMed with a rating of Buy and set a new price target of $55.00
Morgan Stanley initiated coverage of CervoMed with a rating of Overweight and set a new price target of $35.00
Canaccord Genuity initiated coverage of CervoMed with a rating of Buy and set a new price target of $50.00
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, Medical Science in October 2024. Dr. Ordonez was previously Chief Medical Officer at two biotech companies and has significant expertise with both early and late-stage drug development. She previously led clinical development programs in cystic fibrosis and multiple sclerosis at Vertex and Biogen, respectively. Additionally, Mark De Rosch, Ph.D., FRAPS, recently jo
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the advances made by the company towards developing the first treatment for Dementia with Lewy bodies (DLB) BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, announced today it was awarded by the Galien Foundation the Prix Galien USA 2024 prize in the Best Startup category. Cervomed was selected as one of two recipients from a total of 43 nominees in the Best Start
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's Management will participate in the following investor conferences during the month of November: Sidoti Virtual Micro Cap ConferenceFormat: Corporate presentation Date: Thursday, November 14, 2024Time: 2:30 PM ETWebcast Link: click here Stifel 2024 Healthcare ConferenceFormat: Corporate presentation Date: Tuesday, November 19, 2024Time: 3:00 PM ETWebcast Link: click here The webcast of the presentations will be accessible in the Investor section of the CervoMed website https://www.cervomed
Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB Neflamapimod treatment previously led to significant reduction in plasma GFAP levels (p=0.015 versus placebo) and these reductions were associated with an improvement in clinical outcomes The RewinD-LB Phase 2b clinical study successfully enrolled a DLB patient population that is optimized to show the treatment effect of neflamapimod when topline data are reported in December BOSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on d
• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of patients enrolled in RewinD-LB completed the 16-week portion of the study, of which 98% continued into the open label extension BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced the Last Patient Last Visit in RewinD-LB, a Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB). CervoMed remains on track to report
BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John Alam, Chief Executive Officer, is scheduled to participate in a panel discussion and one-on-one investor meetings at the 3rd Annual ROTH Healthcare Opportunities Conference, being held in New York, NY, on October 9, 2024. Panel DetailsTitle: "Opportunities and Challenges When Small Names Go After Blockbuster Indications"Date: Wednesday, October 9, 2024Time: 8:00am ET About CervoMedCervoMed Inc. (the "Company") is a clinical-stage company focused on developing treatments for age-related neurolog
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver two oral presentations that inform on the potential of neflamapimod as a treatment for patients with dementia with Lewy bodies (DLB) at the Clinical Trials on Alzheimer's Disease Conference (CTAD) taking place October 29 – November 1, 2024, in Madrid, Spain. "We are delighted that both of our abstracts have been accepted as late-breaking oral presentations at this year's CTAD," said John Alam, MD, Chief Executive Officer of CervoMed. "This recognition by the conference scientific committ
BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's management will participate in the following investor conferences during the month of September: Morgan Stanley 22nd Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Friday, September 6, 2024Time: 1:50 PM ETWebcast Link: click here H.C. Wainwright 26th Annual Global Investment ConferenceFormat: Corporate PresentationDate: Wednesday, September 11, 2024Time: 8:30 AM ETWebcast Link: click here The webcast of these presentations will be accessible in the Investor section of the C
- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in June 2024; topline data expected in December 2024 - - Hosted a virtual key opinion leader event in July 2024 highlighting neflamapimod's potential for patients with early-stage DLB – - Completed private placement for up to $149.4 million of potential proceeds with leading institutional healthcare investors in April 2024 – - Added to the Russell 2000® and Russell 3000® Indexes effective July 1, 2024, as part of the 2024 Russell U.S. Indexes annual reconstitution -
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings. Presentation Details Format: Fireside ChatDate: Tuesday, August 13, 2024Time: 12:30 PM ETWebcast Link: https://wsw.com/webcast/canaccord98/crvo/2485318 The webcast of the fireside chat will be accessible in the Investors section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMe
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
4 - CervoMed Inc. (0001053691) (Issuer)
8-K - CervoMed Inc. (0001053691) (Filer)
10-Q - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
8-K - CervoMed Inc. (0001053691) (Filer)
424B3 - CervoMed Inc. (0001053691) (Filer)
EFFECT - CervoMed Inc. (0001053691) (Filer)
424B3 - CervoMed Inc. (0001053691) (Filer)
EFFECT - CervoMed Inc. (0001053691) (Filer)
S-3 - CervoMed Inc. (0001053691) (Filer)
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $65 price target.
Brookline Capital analyst Tyler Bussian initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target of $63.
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its expected addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective when the U.S. equity markets open on Monday, July 1, 2024, according to the final preliminary list of 2024 additions posted on the FTSE Russell website on June 21st 2024.
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result -BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB).
Jones Trading analyst Soumit Roy initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target of $70.
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share. Virios Therapeutics shares dipped 47.6% to $0.1850 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers MultiMetaVerse Holdings Limited (NASDAQ:MMV) shares jumped 224% to $2.01. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. GT Biopharma, Inc. (NASDAQ:GTBP) rose 146% to $7.64. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Tantech Hold
CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition.
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.39) by 5.13 percent. This is a 78.97 percent increase over losses of $(1.95) per share from the same period last year. The company reported quarterly sales of $2.35 million which beat the analyst consensus estimate of $1.35 million by 73.85 percent.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Canaccord Genuity boosted the price target for CervoMed Inc. (NASDAQ:CRVO) from $50 to $65. Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating. CervoMed shares fell 5.3% to close at $20.50 on Friday. See how other analysts view this stock. Susquehanna increased the price target for Transocean Ltd. (NYSE:RIG) from $5.5 to $9. Susquehanna analyst Charles Minervino upgraded the stock from Neutral to Positive. Transocean shares fell 0.2% to close at $6.53 on Friday. See how other analyst
Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $50 to $65.